Pharmaceutical Companies Have 'Limited' Experience of REMS Plans

Best Practices' latest report looks at trends in supporting risk mitigation programmes in the pharmaceutical industry.

Many companies in the pharmaceutical industry only have limited experience of implementing risk evaluation and mitigation strategy (REMS) plans, a study has found.

Consulting firm Best Practices questioned 22 representatives from 19 leading pharmaceutical, biotechnology and medical device companies to analyse trends in supporting risk mitigation programmes.

Companies must now be able to develop effective REMS plans to help protect the public and ensure patients have access to their products.

But Best Practice observed that most companies have little experience of doing so.

Researchers found that, on average,